2. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol. Rec. 2007; 82: 93–104.

3. WHO (2011). Estimated Hib and pneumococcal deaths for children under 5 years of age. http://www.who.int

4. Putz K., Hayani K., Zar F.A. Meningitis. Primary Care. Clinics in Office Practice 2013; 40(3): 707–26.

5. Weisfelt M., van de Beek D., Spanjaard L., Reitsma J.B., de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. 2006; 5: 123–9.

6. Marrie T.J., Tyrrell G.J., Majumdar S.R., Eurich D.T. Invasive pneumococcal disease: still lots to learn and a need for standardized data collection instrument. Am. J. Med. 2018; 131(1): 1–7. https://doi.org/10.1016 /j.amjmed. 2017.06.039

7. Backhaus E., Berg S., Anderson R. et al. Epidemiology of in pneumococcal infections: manifestations, incidence and case rate correlated for age, gender and risk factors. BCM Infec. 2016; 16: 367–72.

8. Boronina L.G., Samatova E.V., Drui A.E., Panina E. Yu., Kochneva N.A., Vodovoz N.Yu., Murunova N.V., Gruzdev A.I., Lakhno T.I. [The prevalence of different Streptococcus pneumoniaе serotypes in the children presenting with ENT infections or carrying nasopharyngeal pathogens]. Vestnik otorinolaringologii 2013; (5): 54–8. (In Russ.).

9. Baranov A.A., Namazova-Baranova L.S., Brico N.I., Lobzin Yu.V., Коzlov R.S., Kostinov M.P., Koroleva I.S., Rudakova A.V., Sidorenko S.V., Tatochenko V.K., Kharit S.M., Fedoseenko M.V., Vishneva E.A., Selimzyanova L.R. [Vaccine Prevention of Pneumococcal Infection in Children]. Pediatricheskaya farmakologiya 2018; 15(3): 200–11. (In Russ.). https://doi.org/10.15690/pf.v15i3.1899

10. [Recommendations of the expanded meeting of the Council of Experts initiated by the Union of Pediatricians of Russia on the topic: «The burden of pneumococcal diseases in Russia» (Moscow, February 3, 2009)]. Voprosy sovremennoy pediatrii 2009, 8(2): 104–8. (In Russ.).

11. [Statistical materials of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. Federal center for hygiene and epidemiology. Information about infectious and parasitic diseases (form 2)], Moscow, 2018. (In Russ.). www.fcgie.ru

12. Koroleva I.S., Koroleva M.A., Beloshitsky G.V. [Meningococcal infection and purulent bacterial meningitis in the Russian Federation. 2018. Information and analytical review]. Мoscow: Russian reference center for monitoring bacterial meningitis 2019; 27–33. (In Russ.).

13. Swartz M.N. Bacterial meningitis – a view of the past 90 years. N. Engl. J. Med. 2004; 351(18): 1826–28.

14. Austrian R. Pneumococcal vaccine development and prospects. J. Med. 1979; 67: 547–9.

15. Plouffe J., Breiman R., Falklam R. Bacteremia with Streptococcus pneumoniae in adults: implication for therapy and prevention. JAMA 1996; 275: 194–8.

16. Kostyanaya I.E., Meisner A.F., Aksenova V.A., Baturo A.P. [Experience of using Pneumo 23 and Vaxigrip vaccines in children infected with Mycobacterium tuberculosis from risk groups]. Vaktsinatsiya 2002; (1): 10–1. (In Russ.).

17. Bukhtiyarova I.V., Briko N.I. (eds.). [Vaccinoprophylaxis of the working population: a Guide for doctors]. Moscow: Meditsinskoye informatsionnoye agentstvo, 2019. 192 p. (In Russ.).

18. Rubin L.G. Pneumococcal vaccine. Pediatr. Clin. North Am. 2000; 47: 269–85.

19. Simberkoff M.S., Cross A.P., Al-Ibrahim M., Baltsch A.L., Geiseler P.J., Nadler J., Richmond A.S., Smith R.P., Schiffman G., Shepard D.S., van Eeckhout J.P. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration cooperative study. N. Engl. J. Med. 1986; 315: 1318–27.

20. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2000; 49(RR-9): 1–35.

21. Joloba M.L., Windau А., Bajaksouzian S., Appelbaum P.C., Hausdorff W.P., Jocobs M.R. Pneumococcal Conjugate Vaccine Serotypes of Streptococcus pneumoniae Isolates and the Antimicrobial Susceptibility of Such Isolates in Children with Otitis Media. Clin. Infect. Dis. 2001; 33: 1489–94.

22. Wysocki J., Galaj A., Omecaca F. et al. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP. PneumoADIP Report, November 2008. www.vaccineamc.org/files/TTP_Codebook.pdf.

23. Prymula R., Peeters P., Chrobok V. et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomized double-blind efficacy study. Lancet 2006; 367(9512): 740–8.

24. CDC. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children – Advisory Committee on Immunization Practices (ACIP), 2010. Weekly 2010; 59(9): 258–61.

25. Richter S.S., Diekema D.J., Heilmann K.P. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob. Agents Chemother. 2014; 58: 6484–9. DOI: 10.1128/AAC.03344-14

26. Camilli R., Ambrosio F., Grosso M. et al. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. Vaccine 2017; 35(35): 4587–93. DOI :10.1016/j.vaccine.2017.07.010

27. Mayanskiy N.A., Alyabieva N., Ponomarenko O., Lazareva A., Katosova L., Ivanenko A. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int. J. Infect. Dis. 2014; 20: 58–62.

28. Lobzin Yu.V., Sidorenko S.V., Harit S.M., Belanov S.S., Volkova M.O., Gostev V.V., Alekseyenko S.I., Petrova S.I., Sergeyeva E.V., Koroleva I.S., Orlov A.V., Frolova E.Ya. [Streptococcus pneumoniae serotypes that cause leading nosological forms of pneumococcal infections]. Infectologiya 2013; 5(4): 35–41. (In Russ.).

29. Koroleva I.S., Beloshitsky G.V., Koroleva M.A., Melnikova A.A. [Epidemiological aspects of pneumococcal meningitis in the Russian Federation]. Epidemiologiya i vaccinoprofilaktika 2016; 15(5): 6–13. (In Russ.).

30. Prevention of Pneumococcal Disease Among Infants and Children – Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2010; 59(RR-11): 1–18.

31. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Weekly 2013; 62(25): 521–4.

32. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: What is the supporting evidence? Clin. Infect. Dis. 2011; 52(5): 633–40.

33. Briko N.I., Batyrshina L.R., Briko A.N. [Evaluation of prognostic and economic effectiveness of pneumococcal infection vaccination in working-age men with various chronic diseases]. Zhurnal Microbiologii 2018; (1): 17–23. (In Russ.).

34. Shpagina L.A., Kotova O.S., Shpagin I.S., Loktin E.M., Rukavitsyna A.A., Kuznetsova G.V., Kamneva N.V., Laletina M.A. [Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers]. Terapevticheskiy arkhiv 2018; 90(11): 55–62. (In Russ.). DOI: https://doi.org/ 10.26442/terarkh201890114-61

35. Briko N.I., Korshunov V.A., Namazova-Baranova L.S., Lobzin Yu.V., Baranov A.A., Kostenko N.A., Fedoseenko M.V., Kaуtukova E.V., Vishneva E.V., Tkachenko N.E., Kalуuzhnaya T.A., Shakhtakhtinskaya F.C., Broeva M.I., Semikina E.L., Mayanskiy N.A. [The Results of a Three-Year Pneumococcal Vaccination of Children in Russia]. Pediatricheskaya pharmacologiya 2018; 15(4): 287–99. (In Russ.). https://doi.org/10.15690/ pf.v15i4.1943

36. Baranov A.A., Namazova-Baranova L.S., Mayanskiy N.A., Kulichenko T.V., Lazareva A.V., Alyabyeva N.M., Katosova L.K., Ponomarenko O.A., Ivanenko A.M., Degtyaryova E.A., Kondratenko N.V., Tulupov D.A., Lazareva M.A., Polunina T.A. [Role of Streptococcus pneumoniae in the structure of bacterial infections in the children hospitalized to Inpatient Hospitals in Moscow in 2011–2012. Pediatricheskaya pharmacologiya 2013; 10(5): 6–12. (In Russ.).

37. Mayansky N.A., Alyabyeva N.M., Ponomarenko O.A., Kulichenko T.V., rtemova I.V., Lazareva A.V., Brozhozovskaya E.A., Shamina O.V., Katosova L.K. [Serotypes and Antimicrobial Susceptibility of Nasopharyngeal Pneumococci Isolated from Children in 2010–2016: A Retrospective Cohort Study]. Voprosy sovremennoy pediatrii 2017; 16(5): 413–23. (In Russ.). doi: 10.15690/ vsp.v16i5.1806

38. Pilishvili T., Bennett N.M. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Am. J. Prev. Med. 2015; 49(4): 383–90. DOI: 10.1016/j. vaccine.2015.05.102

39. Savinova T.A., Ilyina E.N., Sidorenko S.V., [Prognosis antipneumococcal vaccination application to control the spread of resistance among pneumococci]. Antibiotiki i chemotherapiya 2011; 56: 3–10. (In Russ.).

40. Sidorenko S., Rennert W., Lobzin Y., Briko N.I. [Multicenter study of serotype distribution of Streptococcus pneumoniae nasopharyngeal isolates from healthy children in the Russian Federation after introduction of PCV13 into the National Vaccination Calendar]. Diagnostic microbiology and infectious disease. 2020; 96(1). https:/doi.org/10.1016/j.diagmicrobio.2019.114914.

41. Mayansky N.A., Savinova T.A., Alyabyeva N.M., Brzhozovskaya E.A., Lazareva A.V., Katosova L.K., Kozlov R.S. [Antimicrobal resistence and clonal evolution of Streptococcus pneumoniae serotype 19A in Russia during 2002–2013]. Clinical Miccrobiology and Antimicrobial Chemotherapy 2017; 19(2): 145–51. (In Russ.).

42. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C. et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 2008; 197: 1016–27.

43. Croucher N.J., Harris S.R., Fraser C., Quail M.A., Burton J., van der Linde M. et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011; 331: 430–4.

44. Wyres K.L., Lambertsen L.M., Croucher N.J., McGee L., von Gottberg A., Linares J. et al. Pneumococcal capsular switching: a historical perspective. J. Infect. Dis. 2013; 207: 439–49.

45. Reinert R.R., Filimonova O.Y., Al-Lahham A., Grudinina S.A., Ilina E.N., Weigel L.M., Sidorenko S.V. Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob. Agents. Chemother. 2008; 52: 2260–2.

46. Savinova T.A., Filimonova O.Yu., Grudinina S.A, Sidorenko S.V. [Genetic diversity of penicillin-resistant Streptococcus pneumoniae]. Zhurnal infektologii 2010; 1(4): 66–71. (In Russ.).

47. Linares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 2010; 16: 402–10.

48. Hackel M., Lascols C., Bouchillon S., Hilton B., Morgenstern D., Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine 2013; 31: 4881–7.

49. Reinert R.R. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin. Microbiol. Infect. 2009; 15(Suppl. 3): 7–11.

50. Spreer A., Lugert R., Stoltefaut V., Hoecht A., Eiffert H., Nau R. Short-term rifampicin pretreatment redu ces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit. Care Med. 2013; 37(7): 2253–8.

51. Bretonniere C., Jozwiak M., Girault C., Beuret P., Trouillet J.L., Anguel N. et al. Rifampin use in acute communityacquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study. Crit. Care. 2015; 19(1): 303. doi: 10.1186/s13054-015-1021-7

52. Imohl M., Reinert R.R., van der Linden M. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. Int. J. Med. Microbiol. 2015; 305(7): 776–83.

53. Weil-Oliver C., van der Linden M., de Schutter I., Dagan R., Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect. Dis. 2012; (12): 207–19

54. Mokaddas E., Albert M.J. Impact of pneumococcal conjugate vaccine on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait. Vaccine 2012; 30(6): 37–40.

55. Regev-Yochay G., Rahav G., Riesenberg K., Wiener-Well Y., Strahilevitz J., Stein M. et al. Initial effects of the national PCV7 childhood immunization program on adult invasive pneumococcal disease in Israel. PloS ONE 2014; (9): e88406. DOI: 10.1371/journal.pone.008840611

56. Olarte L., Kaplan S., Barson W., Romero J., Lin P., Tan T., Hoffman J., Bradley J., Givner L., Mason E., Hulten K. Emergence of multidrug-resistant pneumococcal serotype 35 B among children in the United States. J. Clin. Microbiol. 2017; 55: 724–34. DOI: 10.1128/JCM.01778-16

57. Cornick J.E., Bentley S.D. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microb. Infect. 2012; 14: 573–83.

58. Koroleva M. A., Koroleva I. S., Beloshitsky G. V., Gruber I. M. [Antibiotic susceptibility of Streptococcus pneumoniae, causing meningitis in Moscow. Èpidemiologiȃ i infekcionnye bolezni. Аktual'nye voprosy 2019; (1): 48–55. (In Russ.). DOI: https://dx.doi.org / 10.18565/epidem.2019.1.48-55